It has been more than three decades since the first monoclonal antibody was approved by
the United States Food and Drug Administration (US FDA) in 1986, and during this time …

Lipid-based drug delivery systems, or lipidic carriers, are being extensively employed to
enhance the bioavailability of poorly-soluble drugs. They have the ability to incorporate both …

In this study we tested whether a protein corona is formed around extracellular vesicles
(EVs) in blood plasma. We isolated medium‐sized nascent EVs of THP1 cells as well as of …

In recent years, the unprecedented advances of biomedical nanotechnology have spurred
the development of drug delivery systems (DDSs) based on multifarious nanomaterials in …

Rapid growth in nanotechnology toward the development of nanomedicine agents holds
massive promise to improve therapeutic approaches against cancer. Nanomedicine …

Targeted drug delivery using nanoparticles can minimize the side effects of conventional
pharmaceutical agents and enhance their efficacy. However, translating nanoparticle-based …

Cationic liposomes (CLs) have been regarded as the most promising gene delivery vectors
for decades with the advantages of excellent biodegradability, biocompatibility, and high …

In vivo liposomes, like other types of nanoparticles, acquire a totally new 'biological
identity'due to the formation of a biomolecular coating known as the protein corona that …

Upon contact with a biological milieu, nanomaterials tend to interact with biomolecules
present in the media, especially proteins, leading to the formation of the so-called “protein …

The current understanding of nanoparticle–protein interactions indicates that they rapidly
adsorb proteins upon introduction into a living organism. The formed protein corona …